The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Means for STEM competence for pre- and post-test. حسب Esther Kim (2996622)

الموضوعات:

ECoG timescales decrease during spatial attention. حسب Isabel Raposo (21615517)

"…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …"

Means for global competence pre- and post-test scores. حسب Esther Kim (2996622)

الموضوعات:

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. حسب Shuhuan Zhang (748003)

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. حسب Xiaoqin Li (1399105)

Loss of MAP4K4 expression causes a decrease in the number of neutrophils. حسب Guihua Wang (286390)

Claudin V is decreased following infection with Mtb. حسب Amanda S. Latham (12093638)

"…Exposure to Mtb H37Rv and HN878 decreased claudin V expression compared to uninfected controls in the frontal cortex (E), cerebral nuclei (J), brain stem (O), thalamus (T), and hippocampus (Y). …"

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

<i>Toxoplasma gondii</i> chronic infection decreases visceral nociceptive responses in the absence of macroscopic colonic inflammation. حسب Alexis Audibert (21213531)

FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. حسب Penghui Hu (695020)